Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches
Pharmaceuticals · 10.01.2025 · 18 (1) · 78
DOI: 10.3390/ph18010078 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 10.01.2025. Verfasst von Lucia Centanni und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Endoscopy, IRCCS Hospital San Raffaele, University Vita-Salute San Raffaele, 20132 Milan, Italy. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Inflammatory bowel diseases (IBD) including Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, relapsing conditions characterized by dysregulated immune responses and persistent intestinal inflammation. This review aims to examine new potential therapeutic targets in IBD starting from the STRIDE-II statements. Key targets now include clinical remission, endoscopic remission, and biomarker normalization (such as C-reactive protein and fecal calprotectin). Moreover, histologic remission, transmural remission, and in the future molecular targets are emerging as important indicators of sustained disease control. The treatment goals for inflammatory bowel disease are varied: to relieve symptoms, prevent permanent intestinal damage, promote inflammation remission, and minimize complications. Consequently, the therapeutic targets have evolved to become broader and more ambitious. Integrating these advanced therapeutic targets has the potential to redefine IBD management by promoting deeper disease control and improved patient outcomes. Further research is essential to validate these strategies and optimize their clinical implementation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gastroenterology and Endoscopy, IRCCS Hospital San Raffaele, University Vita-Salute San Raffaele, 20132 Milan, Italy.
- Department of Gastroenterology, INFINY Institute, INSERM NGERE, CHRU de Nancy, Université de Lorraine, F-54500 Vandœuvre-lès-Nancy, France.
ORCID-Profile: Clelia Cicerone, Fabrizio Fanizzi, Ferdinando D'Amico
Zitieren
APA
Centanni, L., Cicerone, C., Fanizzi, F., D'Amico, F., Furfaro, F., Zilli, A., Parigi, T. L., Peyrin-Biroulet, L., Danese, S., & Allocca, M. (2025). Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches. Pharmaceuticals, 18(1), 78. https://doi.org/10.3390/ph18010078
Vancouver
Centanni L, Cicerone C, Fanizzi F, D'Amico F, Furfaro F, Zilli A, et al. Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches. Pharmaceuticals. 2025;18(1):78. doi:10.3390/ph18010078
BibTeX
@article{Centanni2025,
author = {Centanni, Lucia and Cicerone, Clelia and Fanizzi, Fabrizio and D'Amico, Ferdinando and Furfaro, Federica and Zilli, Alessandra and Parigi, Tommaso Lorenzo and Peyrin-Biroulet, Laurent and Danese, Silvio and Allocca, Mariangela},
title = {Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {1},
pages = {78},
doi = {10.3390/ph18010078}
}
EUVIMED